Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial.

Kristin Klemmetsby Solli Zill-E-Huma LatifArild OpheimPeter KrajciKamni Sharma-HaaseJūratė Šaltytė BenthLars TanumNikolaj Kunoe

Published in: Addiction (Abingdon, England) (2018)

Opioid-dependent individuals who elect to switch from buprenorphine-naltrexone treatment after 3 months to extended-release naltrexone treatment for 9 months appear to experience similar treatment completion and abstinence rates and similar adverse event profiles to individuals who had been on extended-release naltrexone from the start of treatment.

Keyphrases

chronic pain
systematic review
pain management
combination therapy
alcohol use disorder
adverse drug